Financiere de Tubize (XBRU:TUB) Other Gross PPE : €0.00 Mil (As of Jun. 2024)

View and export this data going back to 1985. Start your Free Trial

What is Financiere de Tubize Other Gross PPE?

Financiere de Tubize's Other Gross PPE for the quarter that ended in Jun. 2024 was €0.00 Mil.

Financiere de Tubize's quarterly Other Gross PPE stayed the same from Jun. 2023 (€0.00 Mil) to Dec. 2023 (€0.00 Mil) but then increased from Dec. 2023 (€0.00 Mil) to Jun. 2024 (€0.00 Mil).

Financiere de Tubize Other Gross PPE Historical Data

The historical data trend for Financiere de Tubize's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Financiere de Tubize Other Gross PPE Chart

Financiere de Tubize Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

Financiere de Tubize Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Gross PPE	Get a 7-Day Free Trial															-	-	-	-	-

Financiere de Tubize Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Financiere de Tubize Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Financiere de Tubize SA (XBRU:TUB) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

0D53:UK FTD:Germany

Address

Allee de la Recherche, 60, Brussels, BEL, 1070

Website

https://www.financiere-tubize.be

Financiere de Tubize SA is a holding company that owns a stake in UCB, a biopharmaceutical company. UCB is a global biotechnology company that develops treatments for conditions related to neurology and immunology. UCB generates the vast majority of its revenue in the United States, followed by Europe and other international markets. Most of its sales revenue is derived from its neurology products, followed by its immunology products. The company's strategy focuses on leveraging scientific advances and skills in areas such as genetics, biomarkers, and human biology.

Financiere de Tubize Headlines

No Headlines